The differential importation risks of COVID-19 from inbound travellers and the feasibility of targeted travel controls: A case study in Hong Kong
- PMID: 34179860
- PMCID: PMC8214928
- DOI: 10.1016/j.lanwpc.2021.100184
The differential importation risks of COVID-19 from inbound travellers and the feasibility of targeted travel controls: A case study in Hong Kong
Abstract
Background: Many countries/regions implemented strict border measures (e.g., 14-day quarantines) as a blanket policy to prevent COVID-19 importations, while proposed "travel bubbles" as an alternative to reduce the impact of border controls. We aim to examine the differential importation risks with departure origins and post-arrival controls.
Methods: We developed a Bayesian framework to model disease progress of COVID-19 and the effectiveness of travel measures and inferred the origin-specific disease prevalence among inbound travellers, using data on passengers arriving in Hong Kong and laboratory-confirmed imported cases. We estimated the origin-specific risks of releasing infectious travellers under different control strategies and traveller volumes. We also estimated the risk of having released infectious travellers when a resurgence occurs in departure locations with no imported cases during a certain period.
Findings: Under the then strict controls of 14-day quarantine and testing on day 12, the Philippines imposed the greatest importation risk among the studied countries/regions (95.8% of releasing at least one infectious traveller, 95% credible interval (CrI), 94.8-96.6%). This was higher than that from low prevalence countries/regions (e.g., 23.4%, 95% CrI, 21.6-25.3% for Taiwan) if controls relaxed (i.e., 7-day quarantine and test on day 5). Increased traveller volumes and resurgence in departure locations with low prevalence under relaxed controls did not impose a greater importation risk than high prevalence locations under stricter controls.
Interpretation: Moderate relaxation of control measures for travellers arriving from low prevalence locations did not impose higher risks of community outbreaks than strict controls on travellers from high prevalence locations.
Funding: Health and Medical Research Fund, Hong Kong.
© 2021 The Author(s). Published by Elsevier Ltd.
Conflict of interest statement
BJC consults for Roche, GSK, Moderna, AstraZeneca and Sanofi Pasteur and is supported by the AIR@innoHK program of the Innovation and Technology Commission of the Hong Kong SAR Government. SGS reports unpaid consulting for Sanofi Pasteur. The authors report no other potential conflicts of interest.
Figures
 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                References
- 
    - World Health Organization. Archived: WHO Timeline - COVID-19 [Internet]. 2020 [cited 2020 Dec 10]. Available from: https://www.who.int/news-room/detail/27-04-2020-who-timeline—covid-19?gc....
 
- 
    - Summers D.J., Cheng D.H.-Y., Lin P.H.-H., Barnard D.L.T., Kvalsvig D.A., Wilson P.N. Potential lessons from the Taiwan and New Zealand health responses to the COVID-19 pandemic. Lancet Reg Heal - West Pacific. 2020;4(0) https://linkinghub.elsevier.com/retrieve/pii/S2666606520300444 [Internet]Oct [cited 2020 Nov 3]Available from: - PMC - PubMed
 
 
        